J&J wins full ap­proval for blad­der can­cer drug

The FDA on Fri­day con­vert­ed its ac­cel­er­at­ed ap­proval of John­son & John­son’s blad­der can­cer drug Balver­sa to a full ap­proval.

Balver­sa, al­so known as erdafi­tinib, be­came the first FDA-ap­proved FGFR ki­nase in­hibitor in 2019 af­ter a small­er study showed that al­most one-third of blad­der can­cer pa­tients saw their tu­mors shrink. The full ap­proval comes six weeks ahead of sched­ule and fea­tures sev­er­al changes to the la­bel.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.